Fresenius Kabi wins FDA approval for Rituxan biosimilar in US market

Reuters2026/08/03 06:29

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared a rituximab biosimilar for the US market, strengthening Fresenius Kabi’s oncology and immunology biosimilars portfolio.
Dr. Reddy’s Laboratories developed, manufactured, and filed the product; Fresenius Kabi holds exclusive US marketing rights under a deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fresenius Kabi wins FDA approval for Rituxan biosimilar in US market

You may also like

Crypto prices